Informație de încredere. Sprijin real.

Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.

Spațiu publicitar disponibil — bannerul mare de susSpațiu publicitar disponibil — bannerul mare de sus

Explorează temele

Caută tot →

Sănătate mintală și neurodezvoltare

Afecțiuni neurologice

Articole și ghiduri recomandate

PresăAutismÎncredere înaltă20.06.2026

Autism Mutations Converge on Shared Early Brain Pathways

Research demonstrates that hundreds of genetically diverse causes of autism dysfunction converge on common molecular pathways during early brain development. This finding suggests potential shared therapeutic targets despite the genetic heterogeneity of autism spectrum disorder.

StudiuAutism + ADHDÎncredere bună20.06.2026

Pathogenesis of Comorbid Epilepsy in Alzheimer's Disease and the Role of Perampanel as an AMPA Receptor Inhibitor

Alzheimer's disease and epilepsy frequently co-occur and share common pathogenic mechanisms involving AMPA-type glutamate receptors. Perampanel, an FDA-approved AMPAR antagonist for seizure management, may offer therapeutic benefits in patients with comorbid AD-epilepsy, particularly those with myoclonus or sleep disturbances, though clinical evidence remains limited.

StudiuAutism + ADHDÎncredere înaltă20.06.2026

Mental Health Problems in Traumatic Spinal Cord Injury Patients: An Umbrella Systematic Review

This umbrella systematic review synthesized 20 systematic reviews to assess the prevalence and correlates of mental illness in traumatic spinal cord injury patients, finding depression (up to 43%), PTSD (up to 62%), anxiety (27%), and hazardous alcohol use (≥50%) as major concerns. Common risk factors included pain, injury severity, low social support, and maladaptive coping, though evidence for effective interventions was limited.

StudiuAutism + ADHDÎncredere bună20.06.2026

TGF-β1 Pathway as a Possible Link Between Alzheimer's Disease and Depression: Antidepressant Therapeutic Potential

This review examines whether Alzheimer's disease and major depressive disorder share common pathophysiological mechanisms, particularly through reduced TGF-β1 cytokine levels and amyloid-beta accumulation. The authors discuss emerging evidence that certain antidepressants (SSRIs, SNRIs, ketamine) may have neuroprotective effects, though they note the evidence remains inconsistent and potentially adverse effects require further investigation.